Analysis of telomeric single-strand overhang length in human endometrial cancers  by Hashimoto, Manabu et al.
FEBS 29554 FEBS Letters 579 (2005) 2959–2964Analysis of telomeric single-strand overhang length in human
endometrial cancers
Manabu Hashimotoa, Satoru Kyoa,*, Kenkichi Masutomib, Yoshiko Maidaa, Junko Sakaguchia,
Yasunari Mizumotoa,b, Mitsuhiro Nakamuraa, William C. Hahnb, Masaki Inouea
a Department of Obstetrics and Gynecology, Graduate School of Kanazawa University, 13-1, Takaramachi, Kanazawa, Ishikawa 920-8641, Japan
b Department of Medical Oncology, Dana-Farber Cancer Institute and Departments of Medicine, Brigham and Womens Hospital and Harvard
Medical School, 44 Binney Street, Boston, MA 02115, USA
Received 3 March 2005; revised 10 April 2005; accepted 11 April 2005
Available online 29 April 2005
Edited by Varda RotterAbstract The 3 0 single-strand telomeric overhang (3 0-OH) is a
key component of telomere structure. Although telomere length
has been well analyzed in a variety of human cancers, no infor-
mation is available on the 3 0-OH length in cancers. In the present
study, we examined the 3 0-OH length in normal and malignant
endometria using telomere-oligonucleotide ligation assay.
Although 3 0-OH lengths varied among patients, 3 0-OH length
observed in endometrial cancers was signiﬁcantly shorter than
that found in samples derived from normal endometria
(P < 0.001: Students t-test), suggesting that erosion of 3 0-OH
length induces impaired telomeric integrity and genomic instabil-
ity, leading to carcinogenesis. Interestingly, we found that the
most aggressive subtypes of endometrial cancers harbored signif-
icantly longer 3 0-OH length than those with non-aggressive sub-
types (P < 0.001: Sheﬀes test), suggesting that cancer cells with
long 3 0-OH length have growth advantage due to their stabilized
telomere ends. In contrast, we failed to observe an association
between overall telomere length and any clinicopathological
characteristics of endometrial cancers. These ﬁndings suggest
that erosion of 3 0-OH length, rather than overall telomere
length, play roles in endometrial carcinogenesis. Furthermore,
long 3 0-OH may serve as a molecular marker for aggressive phe-
notype of tumors.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Normal human cells exhibit limited proliferative potential.
At least two mechanisms are postulated to restrict cell lifespan,
extrinsic physiological stresses and a cell intrinsic counting
mechanism [1,2]. Several lines of evidence implicate telomere
length as a possible mechanism to count cell divisions as pro-
gressive telomere shortening occurs during successive cell divi-
sions. Consistent with this hypothesis is the observation that
ectopic expression of the catalytic component of telomerase
(hTERT) in normal human cells halts telomere erosion and
permits telomerase-expressing cells to bypass senescence in*Corresponding author. Fax: +81 76 234 4266.
E-mail address: satoruky@med.kanazawa-u.ac.jp (S. Kyo).
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doi:10.1016/j.febslet.2005.04.021some cell types [3–5]. However, recent work suggests that
shortened telomeres are not always linked to senescence; some
normal cells enter senescence with relatively long telomeres
while there are many examples of cells that have much shorter
telomeres than those found in senescent cells yet retain the
ability to divide [6,7]. Thus, while telomere length plays a role
in limiting cell lifespan, other aspects of telomere structure
may also contribute.
Telomeric DNA consists of a double-stranded array of
TTAGGG repeats, which terminates in a 3 0 single-strand G-
rich overhang (3 0-OH) [8,9]. This single strand overhang is a
critical component of telomere structure that is required for
proper telomere function [10,11]. Recent work indicates that
in normal cells alterations in the 3 0-OH correlated with the on-
set of cellular senescence [12].
Telomere length within human cancer cells is often main-
tained at a relatively short length by the function of telomerase
[13,14]. Such stabilized telomeres contribute to continuous and
inﬁnite dividing of cancer cells, leading to cancer progression.
In contrast, 3 0-OH length has not been examined in human
cancers. In the present study, we for the ﬁrst time examined
the 3 0-overhang length in human normal and malignant tissue
samples.2. Materials and methods
2.1. Tissue samples
Surgical tissue specimens were obtained from patients who under-
went hysterectomy to treat primary endometrial cancers or benign tu-
mors such as uterine myomas at the Department of Obstetrics and
Gynecology, Kanazawa University Hospital. All cancers and normal
endometria were histologically conﬁrmed and diagnosed by two inde-
pendent pathologists. All samples were collected after obtaining writ-
ten, informed consent from the patients. Half of each tissue sample
was histologically examined, and the remaining half of each sample
was frozen at 80 C until DNA extraction. The stage and grade of
tumors were determined using the surgical staging systems of FIGO
[15]. The 63 endometrial cancer samples consisted of 59 endometrioid
adenocarcinoma, 1 serous papillary adenocarcinoma, 1 clear cell ade-
nocarcinoma, 31 grade 1 tumors, 21 grade 2 tumors, 7 grade 3 tumors
and 4 tumors with unknown grade; 47 were stage I, 6 were stage II, 9
were stage III. Genomic DNAs were extracted from frozen specimens
according to the standard procedures [16].
2.2. Cell lines
Human umbilical vein endothelial cells (HUVEC) were purchased
from Cambrex Bio Science Walkersville, Inc. and cultured according
to the manufacturers recommendation.blished by Elsevier B.V. All rights reserved.
Fig. 1. Comparison of the T-OLA (telomeric overhang oligonucleo-
tide ligation assay) and non-denatured Southern blot analysis for
measuring the 3 0-OH length. (A) DNA samples from HeLa, C33A and
CaSki cells were subjected to T-OLA. The band intensity of ligated
products in gels was quantiﬁed by NIH Image, described as relative 3 0-
OH length and shown below the panel, in which the relative band
intensity of HeLa cells was normalized to 1.0. To verify equal amounts
of input DNA, quantitative PCR was done on each T-OLA sample
using primers directed against the genomic GAPD locus. M: DNA size
marker. (B) DNA samples from HeLa, C33A and CaSki cells were
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Telomere-oligonucleotide ligation assay (T-OLA) was performed as
described [12,17]. Brieﬂy, 5 lg of genomic DNA was used in a 20 ll
reaction volume containing 0.5 pmol 32P-end-labeled oligonucleotide
of the sequence (CCCTAA)4. We hybridized for 12–15 h at 50 C fol-
lowed by ligation using 20 units of Taq DNA ligase at 50 C for 5 h.
After ligation, products were precipitated and resuspended in water
and denatured in a formamide-based loading buﬀer and separated
on 5% acrylamide, 6 M urea gels. To ensure equal DNA loading of
T-OLA gels, 10 ng of every T-OLA samples were used as template
for quantitative PCR reaction for the genomic GAPDH gene. As a
control to evaluate the relative length of 3 0-overhang, HeLa cells were
subjected to the T-OLA analysis. The band intensity of ladders visual-
ized on gels were quantiﬁed by NIH image.
2.4. Non-denatured southern blot analysis
DNA samples were digested with Hinf1 and RsaI and electrophore-
sed on 0.6% agarose gels, blotted onto nitrocellulose membrane, and
then hybridized [32P]ATP-labeled (CCCTAA)4 probe for 16 h at 37
in hybridization buﬀer. After removal of excess hybridization buﬀer,
the ﬁlters were washed twice with 2X SSC (1X = 0.15 M NaCl,
0.015 M sodium citrate) with 0.1% SDS for 1.5 h at room temperature,
and twice in 0.2X SSC with 0.1% SDS for 15 min each at 50 C, and
then exposed for autoradiography. The radioactivity of the probes
annealing to the 3 0-OH was quantiﬁed with a Fuji Film BAS 2000
Bio-Imaging (Fujiﬁlm, Tokyo, Japan).
2.5. TRF analysis
Telomere length was analyzed by the TRF length assay using a Telo-
TTAGGG Telomere Length Assay Kit (Rosche). Brieﬂy, genomic
DNA was isolated from cells, and then analyzed by Southern blots
probed with a telomere-speciﬁc probe to visualize the TRF.
2.6. Quantitative TRAP assay
Quantitative Telomeric Repeat Ampliﬁcation Protocol (TRAP) as-
says were performed using TRAPeze telomerase detection kit (Invitro-
gen NY, USA).subjected to non-denatured Southern blot analysis. The radioactivity
of the probes annealing to the 3 0-OH was quantiﬁed by NIH Image,
described as relative 3 0-OH length and shown below the panel in which
the relative band intensity of HeLa cells was normalized to 1.0. Values
represent the means ± S.D. from triplicate assays.3. Results
To determine 3 0-OH in human cancers, we used two diﬀerent
assays to measure 3 0-OH length in cancer cell lines. Speciﬁ-
cally, we used the telomere-oligonucleotide ligation (T-OLA)
assay [12,17] and telomere-speciﬁc Southern blot analysis un-
der non-denaturing conditions on three cervical cancer cell
lines, HeLa, C33A and CaSki (Fig. 1). In the T-OLA assay,
radiolabeled oligonucleotides complementary to the telomeric
overhang are annealed to genomic DNA, ligated and then elec-
trophoretically separated. The length of the ligation products
and their radioactive intensity provide an indication of the
length of the overhang present in the sample. We found that
each cell line exhibited distinct 3 0-OH lengths. When the signal
intensity of ligated products in HeLa cells were normalized to
1.0, C33A cells had longer overhangs (4.6) and CaSki had
shorter overhangs (0.95) (Fig. 1A). In non-denatured Southern
blot analysis, genomic DNA was run on non-denaturing gels
and then was hybridized with the radiolabeled oligonucleotide
probe complementary to the telomeric repeats. The radioactive
intensity of the band represents an indication of 3 0-OH length.
When the signal intensity of the bands in HeLa cells were nor-
malized to 1.0, C33A had longer 3 0-OH (2.6) and CaSki had
shorter overhangs (0.63) (Fig. 1B). Thus, both assay systems
exhibited the similar results.
To further examine whether our assay systems correctly de-
tect the 3 0-OH length, the change in 3 0-OH length was moni-
tored during in vitro culture of human umbilical veinendothelial cells (HUVEC). The telomere length constantly
shortened with progressive population doublings (PDs) and ﬁ-
nally reached to an average of 6.5 kb at PD 13 when cells
stopped proliferating and entered senescence (Fig. 2A). The
3 0-OH length exhibited a characteristic change, being relatively
constant in early passage, followed by an abrupt drop at
PD11-13, revealed by the T-OLA assay (Fig. 2B). At the senes-
cent state at PD 13, more than 70% of the signal intensity was
observed in products <100 nt. This is consistent with the pre-
vious report that during senescence most overhangs drop to
just below 100 nt, potentially disrupting normal telomeric
structure [12]. A similar change in 3 0-OH length was conﬁrmed
by the non-denatured Southern blot analysis.
Histologically conﬁrmed surgical specimens obtained from
63 patients with documented endometrial cancers or 22 sam-
ples of normal endometria were next examined for 3 0-OH
length using T-OLA assay (Fig. 3). The mean 3 0-OH lengths
of endometrial cancer and normal endometria were
0.62 ± 0.24 and 1.31 ± 0.530, respectively, when normalized
to the 3 0-OH length observed in Hela cells. Thus, the 3 0-
OH length in endometrial cancers was signiﬁcantly shorter
than normal endometria (P < 0.001: Students t-test). We
then examined the correlation between clinicopathological
characteristics of endometrial cancers and 3 0-OH length
Fig. 2. Changes in telomere length and 3 0 telomeric single-strand overhang (3 0-OH) length in cultured human umbilical vein endothelial cells
(HUVEC). (A) Telomere length was examined by Southern blot analysis and measured as teromeric restriction fragments (TRF). (B) DNA samples
from cultured cells at various PD were subjected to the T-OLA. Product sizes are indicated. The radioactivity of ligated products in gels were counted
by NIH Image and described as relative 3 0-OH length. The relative length of cells at PD2 was normalized to 1.0. To verify equal amounts of input
DNA, quantitative PCR was done on each T-OLA sample using primers directed against the genomic GAPD locus. Results of these PCR reactions
are displayed below each T-OLA panel. PD: population doubling. M: DNA size marker.
Fig. 3. Representative results of T-OLA analysis of endometrial cancer and normal endometrial specimens. The relative 3 0-OH length is shown, in
which 3 0-OH length in HeLa cells were normalized to 1.0. Product sizes are indicated. Quantitative PCR of the GAPD locus done on each sample is
displayed in the lower panel.
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Table 1
Correlation between 3 0 single-strand overhang of telomere, telomere length, telomerase activity and clinicopathological characteristics in endometrial
cancers
Parameter 3 0-OH n TRF n TRAP n
Age
<50 0.56 ± 0.15 20 4.9 ± 1.0 20 0.74 ± 0.80 16
P 50 0.64 ± 0.26 43 5.2 ± 1.4 41 0.99 ± 0.88 23
P 0.92 0.77 0.82
Stage
I 0.59 ± 0.19 47 5.0 ± 1.0 47 0.78 ± 0.77 29
II 0.77 ± 0.50 6 5.5 ± 1.6 5 0.92 ± 0.58 5
III 0.65 ± 0.19 9 5.4 ± 2.2 8 1.87 ± 1.22 4
IV 0.51 ± 0.00 1 5.0 ± 0.0 1
P 0.84 0.89 0.13
Grade
Gl #
#
0.54 ± 0.17
0.64 ± 0.18
0.92 ± 0.40 1/12
1/1113 31 5.0 ± 1.0 31 0.90 ± 0.97 21
G2 21 5.0 ± 0.9 20 0.85 ± 0.73 11
G3 7 5.3 ± 1.6 6 0.78 ± 0.74 5
P 0.0002 0.78 0.96
Myometrial invasion
a (no invasion)
#
0.58 ± 0.18
0.55 ± 0.19
0.72 ± 0.29 1/1 5
8 4.7 ± 0.8 8 1.00 ± 1.27 6
b (invasion < l/2 ) 33 4.9 ± 1.0 32 0.96 ± 0.83 20
c (invasion > l/2 ) 21 5.6 ± 2.5 20 0.72 ± 0.69 13
P 0.03 0.11 0.70
LN metastasis
+ 0.64 ± 0.24 58 6.3 ± 1.0 57
– 0.61 ± 0.24 5 5.0 ± 3.0 4
P§ 0.60 0.77
LVSI
+ 0.57 ± 0.15 14 5.61 ± 1.7 14 0.72 ± 0.74 7
– 0.49 ± 0.17 12 4.9 ± 0.8 12 0.84 ± 1.00 9
P§ 0.12 0.09 0.60
3 0-OH: 30 single-strand overhang of telomeres; LN: lymph node; TRF: terminal restriction fragments; LVSI: lymphovascular space involvement;
TRAP: telomeric repeat ampliﬁcation protocol.
#Sheﬀes test.
Kruskal–Wallis test.
§Welchs t-test.
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of 3 0-OH length with clinical staging, lymphnode metastasis,
lymphovascular space involvement, we found a clear correla-
tion of 3 0-OH length with tumor grade (G) and myometrial
invasion (Table 1). Speciﬁcally, grade 3 (G3) cancers charac-
terized by poorly diﬀerentiated components had signiﬁcantly
longer 3 0-OH lengths (mean 0.93 ± 0.40) than G1 cancers
with well-diﬀerentiated components (mean 0.54 ± 0.17) can-
cers (P < 0.001: Sheﬀes test). We also found that G2 cancers
with moderately diﬀerentiated components had intermediate
3 0-OH lengths (mean 0.64 ± 0.18) and the diﬀerence between
G2 and G3 was also statistically signiﬁcant (P = 0.01:
Sheﬀes test). Thus, increasingly 3 0-OH lengths correlated
with the progression of pathological grade of tumors. Endo-
metrial cancers with deep myometrial invasion (depth > 1/2)
had signiﬁcantly longer 3 0-OH (mean 0.72 ± 0.29) than those
with superﬁcial invasion (depth < 1/2) (mean 0.55 ± 0.19),
and this diﬀerence was statistically signiﬁcant (P = 0.037:
Sheﬀes test).
In addition, we analyzed age-related changes in 3 0-OH
length in cancer and normal endometria. While no correla-
tion was observed between patient age and 3 0-OH lengthin cancers, 3 0-OH length in normal endometria exhibited
age-related changes; it was relatively short (mean
1.14 ± 0.40) in elderly patients over age 50 compared to
younger patients (mean 1.51 ± 0.621) although statistical sig-
niﬁcance was marginal (P = 0.053; Students t-test). It is
therefore likely that 3 0-OH length is eroded in aged endome-
trial tissue.
In contrast, we failed to ﬁnd a signiﬁcant correlation be-
tween telomere length and the age of the patients, clinical stag-
ing, lymphnode metastasis or lymphovascular space
involvement (Table 1), when we measured telomere length in
these same patients. Unlike 3 0-OH length, neither tumor grade
nor myometrial invasion signiﬁcantly correlated with telomere
length. We also examined whether a correlation between 3 0-
OH length and telomere length exists in endometrial cancers
and failed to ﬁnd a correlation between them (P = 0.39: Pea-
sons correlation coeﬃcient test) (Fig. 4A). Moreover, we
failed to ﬁnd a signiﬁcant correlation between the levels of tel-
omerase activity and any of the clinicopathological character-
istics (Table 1). Unexpectedly, neither 3 0-OH length nor
telomere length was statistically correlated with levels of telo-
merase activity (Fig. 4B and C).
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Fig. 4. Correlation among telomere-related factors in endometrial cancers. Correlation between 3 0 telomeric single-strand overhang and telomere
length (A), between 3 0 telomeric single-strand overhang and telomerase activity (B) and between telomere length and telomerase activity (C) are
shown. The relative 3 0-OH length is shown, in which 3 0-OH length in HeLa cells were normalized to 1.0.
M. Hashimoto et al. / FEBS Letters 579 (2005) 2959–2964 29634. Discussion
This is the ﬁrst report examining the 3 0-OH of telomeric re-
peats in clinical cancer samples. Using normal and malignant
endometrial samples, we found that endometrial cancers show
evidence of signiﬁcantly shortened 3 0-OH length, compared to
normal endometria. Moreover, we show that poorly diﬀerenti-
ated (grade 3) endometrial cancers or cancers with deep
myometrial invasion had longer 3 0-OH length than well-
diﬀerentiated (grade 1) cancers or those with superﬁcial inva-
sion, respectively. These observations indicate that alterations
in the 3 0-OH correlate with tumor progression and suggest that
such changes play a role in these events.
Grade 3 endometrial cancer is histologically deﬁned as tu-
mor consisted of solid components larger than 50% of cancer
areas, while grade 1 cancer is mainly (larger than 95% of can-
cer areas) composed of glandular structures by FIGO classiﬁ-
cation [12]. Among various clinicopathological parameters,
tumor grade and myometrial invasion are the most important
prognostic indicators of endometrial cancers [15]. Recent
large-scale analysis of treatment outcome of endopmetrial can-
cers [18] has revealed that the actuarial 5-year rates of locore-
gional relapse were 14% for G3 cancers with deep myometrial
invasion, compared to 1% to 3% for other cancers, when trea-
ted with postoperative radiotherapy. Overall survival rates
were 83% to 85% for G1 and G2 cancers; 74% for G3 cancers
with superﬁcial myometrial invasion; and 58% for G3 cancerswith deep myometrial invasion (P < 0.001). In multivariate
analysis, grade 3 was the most important adverse prognostic
factor for relapse and death as a result of endometrial cancer.
Thus, patients with G3 endometrial carcinoma with deep myo-
metrial invasion are at the highest risk of early distant spread
and death. Our ﬁndings therefore suggest that long 3 0-OH was
tightly associated with aggressive features of tumors.
Why is the length of 3 0-OH related to tumor aggressiveness?
Recent evidence suggests that telomeres are stabilized by the
formation of the T-loop at the ends, in which the 3 0 single-
strand overhang invades upstream double-strand telomeric
DNA [10,11]. The formation of the T-loop depends on the
presence of a suﬃcient length of telomeric 3 0-OH. It has been
suggested that at least 100 nt overhang participates in the for-
mation of this structure [9]. Thus, during the selection of can-
cer cells, the acquisition of stabilized 3 0-OH may facilitate
escape from telomere-associated senescence programs or ram-
pant chromosomal instability that threaten cell survival, Inter-
estingly, no statistically signiﬁcant correlation was observed
between telomere length and these clinical parameters. These
ﬁndings suggest that 3 0-OH length, rather than overall telo-
mere length more accurately predicts tumor behavior.
The molecular mechanisms that regulate 3 0-OH length
are still poorly understood although evidence exists to support
the notion that both synthetic and exonucleic activities partic-
ipate in this process. The analysis of telomerase-deﬁcient
mice indicates that signiﬁcant telomere erosion and age- and
2964 M. Hashimoto et al. / FEBS Letters 579 (2005) 2959–2964generation-dependent increases in cytogenic abnormalities are
found in mTERC null mice. Moreover, telomere attrition in
aging mTERC/p53 double null mutant mice promotes the
development of epithelial cancers by a process of fusion-bridge
breakage [19]. Thus, telomere dysfunction causes genomic
instability, leading to cancer initiation [20]. Since the telomeric
overhang has been implicated as a component of telomere
structure [10,11], the critical erosion of 3 0-OH may lead to dys-
functional telomeres triggering genomic instability and cancer
initiation. The 3 0-overhang loss observed in endometrial can-
cers may thus be a result of such genetic instability occurring
during endometrial carcinogenesis.
In summary, we showed the signiﬁcant variation in 3 0-OH
length in clinical cancer samples and it may be a potential novel
molecular marker that reﬂects tumor aggressiveness in endome-
trial cancer. In the cancer cases we examined, only 3 patients
died of diseases and most patients are alive with 5 patients hav-
ing recurrence. Therefore, it is impossible to examine the corre-
lation between 3 0-OH length and prognosis of the patients at
present. Further longitudinal studies are needed to verify the
predictive strength and clinical utility of such observation.
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